Niraparib With Abiraterone Acetate Plus Prednisone as First‐Line Therapy in Patients With Metastatic Castration‐Resistant Prostate Cancer With Homologous Recombination Repair Gene Alterations: Final Analysis of the Asian Subgroup From the MAGNITUDE Study

Key Points

• Assess the effects of niraparib combined with abiraterone acetate and prednisone in patients with specific genetic alterations and prostate cancer.
• Participants included those with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations.
• The therapy regimen consisted of niraparib, abiraterone acetate, and prednisone.
• Final analysis of the Asian subgroup from the MAGNITUDE study.
• The combination therapy demonstrated improved clinical outcomes compared to standard treatments.
• Significant response rates were noted among patients with homologous recombination repair gene alterations.
• Further detailed effectiveness metrics were provided in the comprehensive analysis of the study.